

# Election Statement

*Dagmara Kulis, MA*

## **Please describe your motivation for becoming involved with ISOQOL. How does ISOQOL's mission and vision relate to your work?**

ISOQOL's mission is fully aligned with my work at EORTC, both as Associate Head of the QOL Department and member of the EORTC QOL Group. As one of the leaders in the field of QOL in cancer in various aspects, from development of QOL measures to methodological research to implementation in both clinical research and care, we have been working with ISOQOL very closely, with many members of the QOL Group presenting the results of their research at the Annual Conferences as well as serving important roles within ISOQOL.

This close bond helped me discover ISOQOL back in 2010 and ever since, I have seen the conferences as the best opportunity to meet like-minded people and experts in QOL research. For my area of expertise, there is no better place than the Translation and Cultural Adaptation SIG, a group of highly motivated specialists who have been advancing the field for over 20 years. With clinical research conducted nowadays, as a standard, in an international, multi-lingual setting, high-quality translations are a must and both with my day-to-day work as well as with the SIG's activities, I try to make sure that we address the needs and challenges the field is facing, both on scientific and more operational levels. I am extremely proud of the projects to which I could contribute, resulting in papers leading to new processes and more standardization in the processes of translation and migration of instruments. Having made great friends in the meantime only adds to the importance of ISOQOL in my professional life.

## **Please describe your qualifications and how your experiences will influence your ability to contribute as an ISOQOL Board Member.**

The current ISOQOL Board is composed of representatives of academia and industry. With my profile and experience, I believe I can be a valuable addition to the Board. Working in a European non-profit organization, I can bring an international perspective on QOL research, representing one of the most well-known QOL instrument development group in oncology. While we remain an academic institution, I work with industry on a daily basis and am aware of the practical issues which they face in clinical trials. Furthermore, with many years in leadership positions in the TCA-SIG and as a co-chair of the 2024 annual meeting, I have gained knowledge of how the society works and is organized, which would definitely be an asset if I were to be elected.